Cite
HARVARD Citation
Gonçalves, A. et al. (n.d.). 199TiP A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES). Immuno-oncology technology. p. . [Online].